Earnings / Pharma
Sanofi Raises Its 2026 Guide for a Second Time and Opens the Door to Bigger Deals
Dupixent and new launches drove a clear beat, and the harder question is what replaces the blockbuster when its patent expires in the early 2030s.
Search stocks, ETFs and companies
1 sourced report attached to this file.
Verified identity
Start with the filing record
The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.
- Ticker
- SNY
- CIK
- 0001121404
- Exchange
- Nasdaq
- Universe updated
- 2026-08-22
Market price
Market price
Latest quoteOpens Google
TickerGrove coverage
Latest on Sanofi
Research foundation
Read the filing with the right frame
Company analysis
Revenue, EPS and guidance answer different earnings questions
Revenue is the top-line amount recognized from a company’s activities under its accounting policy.
Company analysis
The three financial statements describe one business from different angles
The income statement records revenue and expenses over a period.
Investing basics
Stocks, ETFs and indexes are different objects
A stock is an ownership interest in one company.